Elizabeth A. Blair

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

Tanguy Y. Seiwert, Zhixiang Zuo, Michaela K. Keck et al. · Clinical Cancer Research · 2014 · 658 citations · Full text

Life Sciences, Genetics, Oncology +17

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson et al. · The Lancet · 2018 · 347 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

Ezra E.W. Cohen, Darren W. Davis, Theodore Karrison et al. · The Lancet Oncology · 2009 · 272 citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Tanguy Y. Seiwert, Corey C. Foster, Elizabeth A. Blair et al. · Annals of Oncology · 2018 · 233 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng et al. · Clinical Infectious Diseases · 2022 · 170 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +15